MGC Pharmaceuticals' latest animal study on its novel COVID-19 treatment 'ArtemiC', revealed the formula causes "no pathological changes" in major organs.
MGC Pharmaceuticals (ASX: MXC), today announced the release of an additional in vivo safety and toxicity study of the company's COVID-19 treatment 'ArtemiC', featuring histology testing of the formulation on rats.
Notably, the study achieved the targeted outcome, which was to achieve no pathological changes or differences between the study groups. These results build upon prior animal studies on ArtemiC which found "no adverse results in standard toxicity measures."
The more recent study, performed on twenty-four mice and spanning over seven days, included 4 groups with three 3 study drug dosages being 48ug, 96ug and 196ug per kg rat, and a control group.
This study included a pathological examination of the organs: liver, heart, brain, spleen, spinal cord, sciatic nerve, both kidneys, lungs, and tongue.
The results concluded there were no pathological changes in all tested animal samples.
Pleasingly, no adverse impacts were recorded on major organs which provides critical information in relation to planning for future clinical studies [on ArtemiC].Roby Zomer, Co-Founder and Managing Director of MGC Pharmaceuticals
These most recent positive results for ArtemiC – which demonstrate no pathological impact on major organs – allow MGC Pharmaceuticals to complete the FDA requirements for toxicology tests in order to progress with new drug development.
ArtemiC is a natural supplement formula based on Artemisinin, Curcumin and other supporting ingredients that share anti-infective, anti-inflammatory, immune-modulatory and antioxidant properties.
The active compounds within ArtemiC have a well-known antiviral and anti-inflammatory ability, which is particularly prudent given that COVID-19 is not always dangerous in and of itself, but rather, it's the body's reaction to coronavirus that often causes health issues.
For some people who contract the virus, their immune system goes into hyperdrive, known as a "cytokine storm" which effectively leads to severe damages to the body secondary to its dysregulated activity.
MGC's latest pre-clinical data on rats will help the company to progress toward future efficacy clinical studies in Phase IIb and Phase III in COVID-19 patients. The Phase IIb study will include efficacy endpoints and dose-finding elements, based on these current animal study results.
Roby Zomer, Co-founder and Managing Director of MGC Pharma, commented: "The histology results provide the Company with important insights into the potential effects of ArtemiCTM on major organs."
To learn more about MGC Pharma, visit the company HQ here.
Disclaimer: Past performance is not an indicator of future performance.
Get the Latest Marijuana News &
Content in your Inbox!
All your support helps The Green Fund keep writing content for all you
marijuana enthusiasts and potential pot stock investors